{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+Dasatinib", "query": { "intervention": "Placebo - Dasatinib" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 14, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+Dasatinib&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-15T22:08:14.454Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07144293", "title": "Improving Physical Ability and Cellular Senescence Elimination in HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV", "Frailty", "Prefrail", "Aging Problems" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "Quercetin", "type": "DRUG" }, { "name": "Placebo - Dasatinib", "type": "OTHER" }, { "name": "Placebo - Quercetin", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 82, "start_date": "2025-12-04", "completion_date": "2026-08-26", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-09-15T22:08:14.454Z", "location_count": 24, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 18 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07144293" }, { "nct_id": "NCT00869401", "title": "Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "dasatinib", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 217, "start_date": "2009-06", "completion_date": "2019-11-15", "has_results": true, "last_update_posted_date": "2020-02-13", "last_synced_at": "2026-09-15T22:08:14.454Z", "location_count": 207, "location_summary": "Hartford, Connecticut • Jacksonville, Florida • Columbus, Georgia + 135 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Bloomington", "state": "Illinois" }, { "city": "Bloomington", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00869401" }, { "nct_id": "NCT00744497", "title": "Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1930, "start_date": "2008-10", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2016-10-17", "last_synced_at": "2026-09-15T22:08:14.454Z", "location_count": 43, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fayetteville, Arkansas + 35 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Corona", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00744497" }, { "nct_id": "NCT00892177", "title": "Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "dasatinib", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 144, "start_date": "2009-10", "completion_date": "2019-07-01", "has_results": true, "last_update_posted_date": "2019-10-21", "last_synced_at": "2026-09-15T22:08:14.454Z", "location_count": 305, "location_summary": "Scottsdale, Arizona • La Jolla, California • Pismo Beach, California + 179 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Pismo Beach", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00892177" }, { "nct_id": "NCT00767520", "title": "Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Exemestane + Dasatinib", "type": "DRUG" }, { "name": "Exemestane + Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2009-02", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2013-02-28", "last_synced_at": "2026-09-15T22:08:14.454Z", "location_count": 4, "location_summary": "Fountain Valley, California • Riverside, California • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00767520" }, { "nct_id": "NCT02874989", "title": "Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Idiopathic Pulmonary Fibrosis (IPF)" ], "interventions": [ { "name": "Dasatinib + Quercetin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 26, "start_date": "2016-12-16", "completion_date": "2019-06-03", "has_results": false, "last_update_posted_date": "2020-05-12", "last_synced_at": "2026-09-15T22:08:14.454Z", "location_count": 2, "location_summary": "Winston-Salem, North Carolina • San Antonio, Texas", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02874989" }, { "nct_id": "NCT01395017", "title": "Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "dasatinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 202, "start_date": "2011-06", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2016-04-08", "last_synced_at": "2026-09-15T22:08:14.454Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01395017" }, { "nct_id": "NCT04685590", "title": "Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer Disease, Early Onset", "Mild Cognitive Impairment" ], "interventions": [ { "name": "Dasatinib + Quercetin", "type": "DRUG" }, { "name": "Placebo Capsules", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 48, "start_date": "2021-12-22", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-09-15T22:08:14.454Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04685590" }, { "nct_id": "NCT05653258", "title": "Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Obesity", "Healthy Lifestyle" ], "interventions": [ { "name": "Lifestyle Intervention", "type": "OTHER" }, { "name": "Dasatinib 100 MG", "type": "DRUG" }, { "name": "Quercetin 1000mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Abdominal adipose tissue biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "DRUG", "PROCEDURE" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2023-10-17", "completion_date": "2028-02-01", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-09-15T22:08:14.454Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05653258" }, { "nct_id": "NCT02043587", "title": "Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphocytic Leukemia", "Adult Lymphoblastic Lymphoma" ], "interventions": [ { "name": "DNR", "type": "DRUG" }, { "name": "VCR", "type": "DRUG" }, { "name": "PEG-asp", "type": "DRUG" }, { "name": "CTX", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Liposomal AraC", "type": "DRUG" }, { "name": "MTX", "type": "DRUG" }, { "name": "LCV", "type": "DRUG" }, { "name": "AraC", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 31, "start_date": "2014-01", "completion_date": "2022-04-14", "has_results": false, "last_update_posted_date": "2022-05-02", "last_synced_at": "2026-09-15T22:08:14.454Z", "location_count": 4, "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 1 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02043587" } ] }